Panelists give an overview of Graft-vs-host Disease and the modern landscape of treatment.
FDA Approval of Axatilimab (Phase 2 AGAVE-201)
Panelists give an overview of chronic graft-vs-host disease, its history of treatment, how it is handled in the modern day, and the study design of AGAVE-201.
Panelists discuss what the AGAVE-201 study displayed.
Panelists discuss where and when sequencing axatilimab becomes appropriate within the clinical setting, as well as safety precautions associated with the drug.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
4
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
5